STOBOCLO AND OSENVELT Q Code: Q5157

Drug & Product Overview

HCPCS Descriptor Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg

HCPCS Added Date October 1, 2025

Manufacturer Celltrion USA

Route of Administration Subcutaneous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection

About STOBOCLO AND OSENVELT

Stoboclo AND Osenvelt is a medication aligned to the HCPCS Q Code: Q5157 for billing, pricing, and reimbursement purposes in the United States. It is an Osteoporosis drug administered via the subcutaneous route and manufactured by Celltrion USA.

According to CMS Drug Use Information: Denosumab is used to treat bone loss (osteoporosis) in people who have a high risk of getting fractures. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases after menopause (in women), as you age, if someone in your family has osteoporosis, or if you take certain medications (such as prednisone) for long periods. This medication works by slowing bone loss to help maintain strong bones and reduce the risk of broken bones (fractures). Denosumab belongs to a class of drugs called monoclonal antibodies. It prevents certain cells in the body (osteoclasts) from breaking down bone. This monograph is about the following denosumab products: denosumab, denosumab-bbdz, denosumab-bmwo, denosumab-bnht, denosumab-desu, denosumab-dssb, denosumab-kyqq, denosumab-nxxp, and denosumab-qbde.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
72606-0037-01	Stoboclo	CELLTRION USA, Inc.	60	60 MG / 1 ML
72606-0038-01	Osenvelt	CELLTRION USA, Inc.	120	120 MG / 1.7 ML

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

STOBOCLO AND OSENVELT Pricing & Reimbursement

Q5157 Private Payer Reimbursement

$28.52 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q4 2026

Denosumab Biosimilar Information:

STOBOCLO AND OSENVELT Approval Date: February 28, 2025

Product Name	HCPCS Code	Active Ingredient	BLA Type
Prolia	J0897	Denosumab	351(a) Originator Product
Jubbonti and Wyost	Q5136	Denosumab	351(k) Interchangeable
Ospomyv and Xbryk	Q5159	Denosumab	351(k) Interchangeable
Stoboclo and Osenvelt	Q5157	Denosumab	351(k) Interchangeable
Bomyntra and Conexxence	Q5158	Denosumab	351(k) Interchangeable
Bildyos and Bilprevda	Q5162	Denosumab	351(k) Interchangeable
Aukelso and Bosaya	Q5161	Denosumab	351(k) Interchangeable
Enoby and Xtrenbo	Q5167	Denosumab	351(k) Interchangeable
Osvyrti and Jubereq	Q5166	Denosumab	351(k) Interchangeable
Oziltus	Q5165	Denosumab	351(k) Interchangeable
Boncresa	Q5171	Denosumab	351(k) Interchangeable
Ponlimsi	Q5173	Denosumab	351(k) Interchangeable

STOBOCLO AND OSENVELT Claims Performance

Claims from Jan 2026 – Aug 2026

Claim Denial Rate 7.93%

Avg. Days to File 5.3days

Avg. Days to Pay 22.8days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore Q5157 claims analytics on FocalPoint →

STOBOCLO AND OSENVELT CPT Administration Codes

CPT Code	Description
96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intramuscular

Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

STOBOCLO AND OSENVELT Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Bone Mass Increase in Men with Osteoporosis Giant Cell Tumor of Bone Glucocorticoid-Induced Osteoporosis Hypercalcemia of Malignancy Multiple Myeloma and Bone Metastasis from Solid Tumors Postmenopausal Women with Osteoporosis at High Risk for Fracture

Drug Class

RANK Ligand Blocking Activity [MoA]RANK Ligand Inhibitor [EPC]

Frequently Asked Questions

Is there an available Stoboclo And Osenvelt billing and coding guide?

Billing and coding information for STOBOCLO AND OSENVELT can be found through Celltrion USA Inc.. Visit Here →

Are there any available Stoboclo And Osenvelt patient assistance programs?

STOBOCLO AND OSENVELT patient assistance information can be found through Celltrion USA Inc.. Visit Here →

Where can I find Stoboclo and Osenvelt prescribing information?

Stoboclo And Osenvelt prescribing information can be found through the link below. Visit Here →

Where can I find Stoboclo And Osenvelt side effect information?

Stoboclo And Osenvelt side effect information can be found at the link below. Visit Here →

Does billing Stoboclo And Osenvelt require wastage modifiers?

CMS does not include STOBOCLO AND OSENVELT (Q5157) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing Q5157. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.